Market Overview:
The global influenza medication market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of influenza, increasing awareness about the benefits of early diagnosis and treatment, and growing demand for antiviral drugs. Based on type, the global influenza medication market is segmented into zanamivir, oseltamivir, peramivir, amantadine, rimantadine, inosine and others. Zanamivir accounted for the largest share of the global influenza medication market in 2017 owing to its high efficacy and safety profile. Based on application, hospitals accounted for the largest share of the global influenza medication market in 2017 due to increased awareness about early diagnosis and treatment among patients visiting hospitals.
Product Definition:
Influenza medication is a type of medication that is used to treat influenza, which is a type of virus. Influenza can cause serious illness, and so it is important to seek medical treatment if you think you may have the virus. The influenza medication can help to reduce symptoms and make you feel better.
Zanamivir:
Zanamivir is a neuraminidase inhibitor. It works by blocking the viral enzyme that catalyzes the release of virus-specific proteins from infected cells. This results in inhibiting viral replication and consequently, lowers your chances of getting sick.
The drug was approved by the U.
Oseltamivir:
Oseltamivir phosphate is an antiviral medication used for the treatment of influenza. It works by blocking the action of the neuraminidase enzyme, which is required for viral replication. Oseltamivir phosphate has been approved by both U.S. FDA and European Medicines Agency (EMA) for use in influenza prevention as well as treatment in 2009 and 2010 respectively.
Application Insights:
Based on application, the global influenza medication market is segmented into hospitals, clinics and pharmacies, and others. Hospitals held the largest share in 2017 owing to high usage of antiviral drugs for treatment and prevention of Influenza A & B at large-scale healthcare facilities. Oseltamivir is a prominent drug used in hospital settings as it reduces mortality more than other drugs against seasonal flu by around 25% when compared with its use alone against seasonal flu.
Clinics are anticipated to be one of the fastest-growing segments over the forecast period due to rising awareness about preventive measures taken against influenza infection along with growing demand for low cost medications that can be administered without medical supervision at home.
Regional Analysis:
North America dominated the global influenza medication market in 2016. The presence of sophisticated healthcare infrastructure, high patient awareness levels coupled with a strong distribution network of key manufacturers is expected to drive growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to increasing demand for generic drugs and rising prevalence of chronic diseases such as respiratory infections and diabetes. Furthermore, growing penetration of modern medical practices due to improving healthcare infrastructure in this region will support market development during the forecast period. In addition, economic development coupled with government initiatives aimed at improving public health system will also boost regional product demand over the next eight years (2030).
The Asia Pacific was followed by Europe which accounted for around 27% share in 2016 owing to higher disease incidence rates along with better clinical management practices adopted by North American countries comparedto Asian countries.
Growth Factors:
- Increasing incidence of influenza and other respiratory infections
- Growing awareness about the benefits of early treatment
- Rising demand for convenient and easy-to-use medication formats
- Increasing investment in research and development of new flu medications
- Proliferation of online pharmacies that offer discounts on prescription drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Influenza Medication Market Research Report
By Type
Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine, Others
By Application
Hospitals, Clinics, Pharmacies, Others
By Companies
Daiichi Sankyo Company, GlaxoSmithKline, Natco Pharma, F. Hoffmann-La Roche, Teva Pharmaceutical, Sandoz International, Sun Pharmaceutical Industries, Mylan, Daiichi Sankyo Company
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
154
Number of Tables & Figures
108
Customization Available
Yes, the report can be customized as per your need.
Global Influenza Medication Market Report Segments:
The global Influenza Medication market is segmented on the basis of:
Types
Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Pharmacies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Daiichi Sankyo Company
- GlaxoSmithKline
- Natco Pharma
- F. Hoffmann-La Roche
- Teva Pharmaceutical
- Sandoz International
- Sun Pharmaceutical Industries
- Mylan
- Daiichi Sankyo Company
Highlights of The Influenza Medication Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Zanamivir
- Oseltamivir
- Peramivir
- Amantadine
- Rimantadine
- Inosine
- Others
- By Application:
- Hospitals
- Clinics
- Pharmacies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Influenza Medication Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Influenza medication is a prescription drug used to treat the flu. It can be taken by mouth or injected into a vein. Influenza medication helps to reduce the severity of symptoms, including fever, cough, and body aches.
Some of the major companies in the influenza medication market are Daiichi Sankyo Company, GlaxoSmithKline, Natco Pharma, F. Hoffmann-La Roche, Teva Pharmaceutical, Sandoz International, Sun Pharmaceutical Industries, Mylan, Daiichi Sankyo Company.
The influenza medication market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Influenza Medication Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Influenza Medication Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Influenza Medication Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Influenza Medication Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Influenza Medication Market Size & Forecast, 2020-2028
4.5.1 Influenza Medication Market Size and Y-o-Y Growth
4.5.2 Influenza Medication Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Zanamivir
5.2.2 Oseltamivir
5.2.3 Peramivir
5.2.4 Amantadine
5.2.5 Rimantadine
5.2.6 Inosine
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Pharmacies
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Influenza Medication Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Influenza Medication Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Zanamivir
9.6.2 Oseltamivir
9.6.3 Peramivir
9.6.4 Amantadine
9.6.5 Rimantadine
9.6.6 Inosine
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Pharmacies
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Zanamivir
10.6.2 Oseltamivir
10.6.3 Peramivir
10.6.4 Amantadine
10.6.5 Rimantadine
10.6.6 Inosine
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Pharmacies
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Zanamivir
11.6.2 Oseltamivir
11.6.3 Peramivir
11.6.4 Amantadine
11.6.5 Rimantadine
11.6.6 Inosine
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Pharmacies
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Zanamivir
12.6.2 Oseltamivir
12.6.3 Peramivir
12.6.4 Amantadine
12.6.5 Rimantadine
12.6.6 Inosine
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Pharmacies
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Zanamivir
13.6.2 Oseltamivir
13.6.3 Peramivir
13.6.4 Amantadine
13.6.5 Rimantadine
13.6.6 Inosine
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Pharmacies
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Influenza Medication Market: Competitive Dashboard
14.2 Global Influenza Medication Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Daiichi Sankyo Company
14.3.2 GlaxoSmithKline
14.3.3 Natco Pharma
14.3.4 F. Hoffmann-La Roche
14.3.5 Teva Pharmaceutical
14.3.6 Sandoz International
14.3.7 Sun Pharmaceutical Industries
14.3.8 Mylan
14.3.9 Daiichi Sankyo Company
